These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 30711384)
41. Colistin-tobramycin combinations are superior to monotherapy concerning the killing of biofilm Pseudomonas aeruginosa. Herrmann G; Yang L; Wu H; Song Z; Wang H; Høiby N; Ulrich M; Molin S; Riethmüller J; Döring G J Infect Dis; 2010 Nov; 202(10):1585-92. PubMed ID: 20942647 [TBL] [Abstract][Full Text] [Related]
42. Pseudomonas aeruginosa Aggregate Formation in an Alginate Bead Model System Exhibits Sønderholm M; Kragh KN; Koren K; Jakobsen TH; Darch SE; Alhede M; Jensen PØ; Whiteley M; Kühl M; Bjarnsholt T Appl Environ Microbiol; 2017 May; 83(9):. PubMed ID: 28258141 [TBL] [Abstract][Full Text] [Related]
43. Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis. Smith AL; Fiel SB; Mayer-Hamblett N; Ramsey B; Burns JL Chest; 2003 May; 123(5):1495-502. PubMed ID: 12740266 [TBL] [Abstract][Full Text] [Related]
44. In vitro interactions of tobramycin with various nonantibiotics against Pseudomonas aeruginosa and Burkholderia cenocepacia. Treerat P; Widmer F; Middleton PG; Iredell J; George AM FEMS Microbiol Lett; 2008 Aug; 285(1):40-50. PubMed ID: 18513356 [TBL] [Abstract][Full Text] [Related]
45. [Infections of the respiratory tract with Pseudomonas aeruginosa in cystic fibrosis]. Winkler U; Wingender J; Jäger KE Klin Wochenschr; 1985 Jun; 63(11):490-8. PubMed ID: 3925219 [TBL] [Abstract][Full Text] [Related]
46. Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients. Bjarnsholt T; Jensen PØ; Fiandaca MJ; Pedersen J; Hansen CR; Andersen CB; Pressler T; Givskov M; Høiby N Pediatr Pulmonol; 2009 Jun; 44(6):547-58. PubMed ID: 19418571 [TBL] [Abstract][Full Text] [Related]
47. Phenotypes of non-attached Pseudomonas aeruginosa aggregates resemble surface attached biofilm. Alhede M; Kragh KN; Qvortrup K; Allesen-Holm M; van Gennip M; Christensen LD; Jensen PØ; Nielsen AK; Parsek M; Wozniak D; Molin S; Tolker-Nielsen T; Høiby N; Givskov M; Bjarnsholt T PLoS One; 2011; 6(11):e27943. PubMed ID: 22132176 [TBL] [Abstract][Full Text] [Related]
48. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Langton Hewer SC; Smyth AR Cochrane Database Syst Rev; 2009 Oct; (4):CD004197. PubMed ID: 19821321 [TBL] [Abstract][Full Text] [Related]
49. Does ivacaftor interfere with the antimicrobial activity of commonly used antibiotics against Pseudomonas aeruginosa?-Results of an in vitro study. Millar BC; Rendall JC; Downey DG; Moore JE J Clin Pharm Ther; 2018 Dec; 43(6):836-843. PubMed ID: 29959786 [TBL] [Abstract][Full Text] [Related]
50. Effect of oxygen limitation on the in vitro activity of levofloxacin and other antibiotics administered by the aerosol route against Pseudomonas aeruginosa from cystic fibrosis patients. King P; Citron DM; Griffith DC; Lomovskaya O; Dudley MN Diagn Microbiol Infect Dis; 2010 Feb; 66(2):181-6. PubMed ID: 19828274 [TBL] [Abstract][Full Text] [Related]
51. Exploratory study of the prevalence and clinical significance of tobramycin-mediated biofilm induction in Pseudomonas aeruginosa isolates from cystic fibrosis patients. Elliott D; Burns JL; Hoffman LR Antimicrob Agents Chemother; 2010 Jul; 54(7):3024-6. PubMed ID: 20404125 [TBL] [Abstract][Full Text] [Related]
52. Low-Dose Nitric Oxide as Targeted Anti-biofilm Adjunctive Therapy to Treat Chronic Pseudomonas aeruginosa Infection in Cystic Fibrosis. Howlin RP; Cathie K; Hall-Stoodley L; Cornelius V; Duignan C; Allan RN; Fernandez BO; Barraud N; Bruce KD; Jefferies J; Kelso M; Kjelleberg S; Rice SA; Rogers GB; Pink S; Smith C; Sukhtankar PS; Salib R; Legg J; Carroll M; Daniels T; Feelisch M; Stoodley P; Clarke SC; Connett G; Faust SN; Webb JS Mol Ther; 2017 Sep; 25(9):2104-2116. PubMed ID: 28750737 [TBL] [Abstract][Full Text] [Related]
53. Antimicrobial resistance, respiratory tract infections and role of biofilms in lung infections in cystic fibrosis patients. Ciofu O; Tolker-Nielsen T; Jensen PØ; Wang H; Høiby N Adv Drug Deliv Rev; 2015 May; 85():7-23. PubMed ID: 25477303 [TBL] [Abstract][Full Text] [Related]
54. Effect of antibiotic co-administration on young and mature biofilms of cystic fibrosis clinical isolates: the importance of the biofilm model. Tré-Hardy M; Macé C; El Manssouri N; Vanderbist F; Traore H; Devleeschouwer MJ Int J Antimicrob Agents; 2009 Jan; 33(1):40-5. PubMed ID: 18801647 [TBL] [Abstract][Full Text] [Related]
55. Occurrence of hypermutable Pseudomonas aeruginosa in cystic fibrosis patients is associated with the oxidative stress caused by chronic lung inflammation. Ciofu O; Riis B; Pressler T; Poulsen HE; Høiby N Antimicrob Agents Chemother; 2005 Jun; 49(6):2276-82. PubMed ID: 15917521 [TBL] [Abstract][Full Text] [Related]
56. Effects of subminimal inhibitory concentrations of antibiotics on the adherence of Pseudomonas aeruginosa to tracheobronchial mucin. Vishwanath S; Guay CM; Ramphal R J Antimicrob Chemother; 1987 May; 19(5):579-83. PubMed ID: 2886486 [TBL] [Abstract][Full Text] [Related]
57. Microevolution of Pseudomonas aeruginosa to a chronic pathogen of the cystic fibrosis lung. Hogardt M; Heesemann J Curr Top Microbiol Immunol; 2013; 358():91-118. PubMed ID: 22311171 [TBL] [Abstract][Full Text] [Related]
58. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis. Waters V; Ratjen F Cochrane Database Syst Rev; 2017 Oct; 10(10):CD009528. PubMed ID: 28981972 [TBL] [Abstract][Full Text] [Related]
59. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis. Waters V; Ratjen F Cochrane Database Syst Rev; 2015 Mar; (3):CD009528. PubMed ID: 25741986 [TBL] [Abstract][Full Text] [Related]